Advertisement
  • Loading metrics

Ebola Virus Entry: A Curious and Complex Series of Events

  • Sven Moller-Tank,

    Affiliations Department of Microbiology, University of Iowa, Iowa City, Iowa, United States of America, Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

  • Wendy Maury

    wendy-maury@uiowa.edu

    Affiliation Gene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

Ebola Virus Entry: A Curious and Complex Series of Events

  • Sven Moller-Tank, 
  • Wendy Maury
PLOS
x

Introduction

Ebola virus (EBOV) belongs to the Filoviridae family of negative-sense RNA viruses. Since its identification in 1976, sporadic outbreaks have occurred in Central Africa. The 2014 outbreak in West Africa provides evidence that EBOV is emerging into new geographic regions. While previous outbreaks have been confined to small areas, the most recent outbreak is atypically widespread with over 25,000 people infected. Evidence from the limited-sequence studies that have been published suggests that the outbreak resulted from a single reservoir-to-human transmission event and subsequent human-to-human spread [1]. As neither an EBOV vaccine nor antivirals are currently available, this outbreak highlights the critical need for the development of effective vaccines and therapeutics.

Infection is initiated by virions entering dendritic cells, macrophages, and, perhaps, hepatocytes [2]. Virus replication in these cells is thought to be critical for initiation of systemic infection, leading to virus spread to new sites with infection of additional cell populations. Thus, a better understanding of virus entry will not only provide insight into both host cell and virus biology, but also elucidate therapeutic targets. Here we provide a brief overview of the current understanding of EBOV entry and identify important questions that remain unanswered in the field.

Filovirus Particles

The uniquely shaped filamentous particles made by filoviruses are surrounded by an envelope acquired during virion budding from the plasma membrane (Fig 1). Recent studies provide evidence that the outer leaflet of the viral envelope contains phosphatidylserine (PtdSer), which serves as an important attachment factor during entry [3,4]. Inside the envelope, the viral matrix proteins VP40 and VP24 line the inner leaflet and provide structural support. Surrounded by this protective layer of lipids and matrix proteins, the RNA genome is associated with several viral proteins, forming the ribonucleoprotein (RNP) complex. A single viral glycoprotein (GP), encoded by the virus, embeds in the viral envelope and is required for virion/cellular membrane fusion. The mature GP is composed of two subunits, GP1 (~140 kDa) and GP2 (~26 kDa), that heterodimerize through disulfide bonds and associate to form trimers (Fig 2). The crystal structure of the EBOV GP reveals that this trimer forms a chalice-like shape, with the GP2 forming the base and GP1 forming the cup [5]. Surrounding and protecting this chalice is the N-glycan-containing cap region and a heavily N- and O-glycosylated mucin-like domain (MLD) of GP1. Glycans on these regions are important for shielding the GP from neutralizing antibodies [6].

thumbnail
Fig 1. Ebola Virus Particle.

An EBOV particle is shown with key viral proteins highlighted, including: the viral glycoprotein, matrix proteins (VP40, VP24), and viral ribonucleoprotein complex (RNA-dependent RNA polymerase, VP30, VP35, nucleoprotein, and RNA).

https://doi.org/10.1371/journal.ppat.1004731.g001

thumbnail
Fig 2. Structure of the EBOV glycoprotein (GP).

(Top) Each monomer of GP consists of a GP1 and GP2 heterodimer associated via a disulfide bond. GP1 contains the receptor binding domain (RBD), protected by a glycan cap and a mucin like domain (MLD) at the apex of the structure. The RBD interacts with the endosomal receptor Niemann-Pick C1 (NPC1) upon proteolytic processing of GP1 that removes the glycan cap and MLD. The fusion loop, which imbeds in the target membrane during fusion, is part of the GP2 monomer, but remains hidden in the mature pre-fusion GP trimer. (Bottom)The GP trimer consists of three GP1/2 heterodimers (shown in different shades) that associate through several GP1/GP2 and GP2/GP2 interactions.

https://doi.org/10.1371/journal.ppat.1004731.g002

Adherence and Internalization

The cell surface interactions of filoviruses differ from other characterized enveloped virus/cell surface receptor interactions in that amino acid residues of EBOV GP are not thought to interact with a cell surface receptor. Instead, these viruses bind to target cells through two types of relatively non-specific receptors: C-type lectins (CLECs) that interact with glycans on EBOV GP and PtdSer receptors that interact with the viral envelope PtdSer (Fig 3A). CLECs (LSECTin, DC-SIGN [dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin], L-SIGN [liver/lymph node-specific ICAM-3 grabbing nonintegrin], mannose-binding lectin, and hMGL [human macrophage galactose- and N-acetylgalactosamine-specific C-type lectin]) bind N- and O-linked glycans on EBOV GP, leading to enhanced EBOV entry, although the details of how these interactions lead to virion internalization have yet to be studied. Cells lacking CLEC expression remain permissive for EBOV infection, providing evidence that CLEC-independent uptake mechanisms also occur. More recently appreciated is the role of cellular receptors that bind to PtdSer present in the viral envelope (reviewed in [7]). These PtdSer receptors include members of the T-cell immunoglobulin and mucin domain (TIM) family, TIM-1 and TIM-4, and protein complexes composed of Gas6 or Protein S and the TAM family of receptor tyrosine kinases, Tyro3, Axl, and Mer. Given that PtdSer is believed to be present on the surface of most, if not all, viral envelopes, it is not surprising that virion entry via virion-associated PtdSer/host PtdSer receptors interactions is not limited to filoviruses, but has recently been observed to mediate entry of a variety of enveloped viruses including flaviviruses, alphaviruses, and baculoviruses. While evidence suggests that TIM-1 can mediate virion internalization without cytoplasmic tail signaling [3,8], mechanistic details of TIM-1-dependent virion uptake are not currently established. In contrast, virus/TAM family receptor interactions trigger a signaling cascade that dampens the cell’s innate immune response, increasing the target cell permissivity [9]. Interestingly, enveloped virus interactions with CLECs may also immunomodulate immune responses of virus-infected DCs [10]. The relative importance of these various cell surface interactions for EBOV entry and pathogenesis, regardless of whether they bind GP glycans or envelope lipids, remains to be characterized in vivo.

thumbnail
Fig 3. Steps of Ebola Virus Entry.

(A) Cell surface receptors bind EBOV particles through interactions with either virion-associated phosphatidylserine or viral glycoprotein glycans. (B) Virus is internalized through ruffling of the plasma membrane and macropinocytosis. (C) During trafficking through endosomes, the EBOV glycoprotein is cleaved by proteases that remove the mucin-like domain (MLD) and glycan cap, exposing the receptor binding domain (RBD). Shown is a stepwise removal of those sequences, although in the cell these cleavage events may occur concurrently. (D) The RBD interacts with NPC1 in the late endosome/lysosome. (E) Binding of the NPC1 C-loop by the glycoprotein is followed by one or more triggers that release the fusion loop, allowing for its insertion into the target membrane. Subsequent transition of the EBOV GP into a six helix bundle results in the host and viral membranes being brought together, leading to fusion. (F) Release of the viral nucleoprotein into the cytoplasm prior to the initiation of virus replication.

https://doi.org/10.1371/journal.ppat.1004731.g003

Ebola virions are thought to be internalized primarily through macropinocytosis (Fig 3B), although other routes of uptake have also been reported [1114]. The mechanism triggering EBOV uptake remains unknown; however, we and others have shown that PtdSer receptor-dependent internalization of viral particles does not require the presence of a viral glycoprotein on the particle [4,15]. Further, virion binding to CLECs or PtdSer receptors has not been shown to directly trigger macropinocytosis, so elucidation of the mechanism eliciting filovirion macropinocytosis is still needed. Another piece of the virion internalization puzzle that remains unsolved is how vesicular stomatitis virus (VSV) pseudovirions that are pseudotyped with EBOV GP internalize via macropinocytosis, whereas VSV containing its native G glycoprotein enters cells through clathrin-coated pits [16,17]. One possible explanation for this apparent disparity is that VSV displaying its native G glycoprotein interacts directly with its recently identified cellular receptor, the ubiquitous LDL receptor [18]. In contrast, the EBOV GP on pseudotyped VSV does not strongly interact with any cell surface receptors and EBOV instead utilizes less specific, lower affinity internalization mechanisms, such as PtdSer/PtdSer receptor and/or glycan/lectin interactions. Potentially, it is through these latter interactions that EBOV macropinocytosis occurs.

Processing and Trafficking

Ebola virions internalize into early endosomes and subsequently traffic to the late endosome/lysosome in a Rab5 and Rab7 GTPase-dependent manner [19]. Within the endosome, low-pH-dependent proteases remove the heavily glycosylated MLD and glycan cap from GP1, resulting in a 17- to 19-kDa protein (Fig 3C) [20,21]. Cathepsins L and B were initially identified as the proteases essential for EBOV GP processing and their cleavage sites within EBOV GP have been mapped [22,23]. However, bacterial thermolysin and proteases present in Vero E6 cells and mouse embryonic fibroblasts can effectively substitute for these cathepsins [20,24]. Proteolytic processing of GP is necessary for exposure of the GP1 receptor binding domain (RBD), but is insufficient to initiate virus fusion at 37°C [5,25]. However, at higher temperatures under low pH and/or mild reducing conditions, the 19-kDa form of the GP binds to liposomes, suggesting that this version of the trimer is in a fusion-ready state [26].

Endolysosomal Receptor Binding

The exposed RBD of the proteolytically primed GP1 binds to the late endosomal/lysosomal protein NPC1 (Fig 3D) [27,28]. This novel endosomal interaction is essential for subsequent filovirus/cell membrane fusion. Whether processed GP interaction with NPC1 directly triggers fusion or subsequent steps are needed remains unclear. Several groups have shown that additional endosomal proteolysis and/or reduction are required for EBOV fusion, but the chronology and endosomal location of these events have yet to be clarified [20,21,26,29].

EBOV membrane fusion events are thought to be similar to those described for other viral glycoproteins [30]. A hydrophobic fusion loop of GP2, normally buried beneath a neighboring GP1 monomer [5], becomes exposed by the fusion trigger (Fig 2 and Fig 3E). Low pH conditions are necessary for conformational changes within the fusion loop that promote fusion [31]. In the form of a fist-like structure, hydrophobic GP2 residues present at the tip of the fusion loop insert into the target membrane [32]. The GP2 trimer unwinds and refolds into a six-helix bundle in which the fusion loop and GP transmembrane domain meet [33]. The resulting fusion pore allows for release of the RNP into the cytoplasm and the start of virus replication (Fig 3F).

Lessons from EBOV Entry Studies and Outstanding Questions

To date, investigation of EBOV entry has led to three paradigm-shifting insights. First, the discovery of PtdSer receptor-mediated entry for not only filoviruses but also for a variety of other enveloped viruses has helped to mechanistically elucidate the broad tropism of some enveloped viruses. Second, recognition of the low pH-dependent endosomal proteolytic processing of EBOV GP identified a novel low-pH-dependent mechanism that has now been shown to be required for a number of enveloped viruses. Third, identifying an endosomal receptor for filoviruses altered the understanding of potential locations of virus/receptor interactions. While this latter observation was initially made for filoviruses, recent studies have shown that lysosomal-associated membrane protein 1 (LAMP1) is a lysosomal receptor for Lassa virus, suggesting this endosomal mechanism of fusion control may be broader than previously appreciated [34].

Despite the progress over the past five years in understanding EBOV entry, many critical questions remain unanswered. For instance, how does PtdSer become enriched on the outer leaflet of enveloped virus membranes? Do virion interactions with CLECs, TIM proteins, or TAM/Gas6 complexes mediate direct internalization of virions into endosomes? If TIM proteins do directly mediate virus internalization, mechanistically, how is this accomplished since some TIM molecules are not thought to signal? Alternatively, do these receptors solely accumulate virions on the surface of cells? If so, is there a yet unidentified cell-surface receptor that is required for EBOV internalization? If PtdSer receptors do directly mediate EBOV internalization, do the different receptors mediate internalization through the same endosomal pathway and into the same endosomal compartment? For those filoviruses that do not require Cathepsin B and L, what endosomal proteases are responsible for their GP processing? What is the role of NPC1? Does NPC1 binding directly lead to EBOV fusion? If so, why are additional proteolysis events required and what protease(s) in which vesicular compartment mediate this second processing step? Finally, in terms of the big picture, what selective advantages are there for enveloped viruses such as filoviruses to use relatively non-specific, low-affinity mechanisms for internalization? Certainly, a growing body of evidence suggests that there must be advantages. These might include a breadth of tropism that would otherwise not be available to enveloped viruses. Further, using these entry mechanisms protects critical RBD and fusion residues from neutralizing antibodies by limiting extracellular exposure of these GP elements; in the current entry model for filoviruses, these sequences are solely exposed late within the endosomal/lysosomal compartments. A better understanding of these paradigm-shifting findings could provide additional drug targets to complement the current repertoire of Ebola virus antivirals in development. No doubt, the continued pursuit of answers to these questions by a number of groups will provide significant insights into both EBOV and, more broadly, virus biology.

References

  1. 1. Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, et al. (2014) Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345: 1369–1372. pmid:25214632
  2. 2. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, Geisbert JB, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163: 2347–2370. pmid:14633608
  3. 3. Meertens L, Carnec X, Lecoin MP, Ramdasi R, Guivel-Benhassine F, Lew E, et al. (2012) The TIM and TAM Families of Phosphatidylserine Receptors Mediate Dengue Virus Entry. Cell host & microbe 12: 544–557.
  4. 4. Moller-Tank S, Kondratowicz AS, Davey RA, Rennert PD, Maury W (2013) Role of the phosphatidylserine receptor TIM-1 in enveloped-virus entry. J Virol 87: 8327–8341. pmid:23698310
  5. 5. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454: 177–182. pmid:18615077
  6. 6. Lennemann NJ, Rhein BA, Ndungo E, Chandran K, Qiu X, Maury W. (2014) Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. MBio 5: e00862–00813. pmid:24473128
  7. 7. Moller-Tank S, Maury W (2014) Phosphatidylserine receptors: Enhancers of enveloped virus entry and infection. Virology 468-470C: 565–580.
  8. 8. Moller-Tank S, Albritton LM, Rennert PD, Maury W (2014) Characterizing Functional Domains for TIM-Mediated Enveloped Virus Entry. J Virol 88: 6702–6713. pmid:24696470
  9. 9. Bhattacharyya S, Zagórska A, Lew ED, Shrestha B, Rothlin CV, Naughton J, et al. (2013) Enveloped Viruses Disable Innate Immune Responses in Dendritic Cells by Direct Activation of TAM Receptors. Cell Host & Microbe 14: 136–147.
  10. 10. Mesman AW, Zijlstra-Willems EM, Kaptein TM, de Swart RL, Davis ME, Ludlow M, et al. (2014) Measles Virus Suppresses RIG-I-like Receptor Activation in Dendritic Cells via DC-SIGN-Mediated Inhibition of PP1 Phosphatases. Cell Host Microbe 16: 31–42. pmid:25011106
  11. 11. Bhattacharyya S, Hope TJ, Young JA (2011) Differential requirements for clathrin endocytic pathway components in cellular entry by Ebola and Marburg glycoprotein pseudovirions. Virology 419: 1–9. pmid:21855102
  12. 12. Hunt CL, Kolokoltsov AA, Davey RA, Maury W (2011) The tyro3 receptor kinase axl enhances macropinocytosis of zaire ebolavirus. J Virol 85: 334–347. pmid:21047970
  13. 13. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA (2010) Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog 6(9):e1001110. pmid:20862315
  14. 14. Nanbo A, Imai M, Watanabe S, Noda T, Takahashi K, Neumann G, et al. (2010) Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner. PLoS Pathog 6(9):e1001121. pmid:20886108
  15. 15. Jemielity S, Wang JJ, Chan YK, Ahmed AA, Li W, Monahan S, et al. (2013) TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine. PLoS Pathog 9: e1003232. pmid:23555248
  16. 16. Cureton DK, Massol RH, Saffarian S, Kirchhausen TL, Whelan SP (2009) Vesicular stomatitis virus enters cells through vesicles incompletely coated with clathrin that depend upon actin for internalization. PLoS Pathog 5: e1000394. pmid:19390604
  17. 17. Piccinotti S, Kirchhausen T, Whelan SP (2013) Uptake of rabies virus into epithelial cells by clathrin-mediated endocytosis depends upon actin. J Virol 87: 11637–11647. pmid:23966407
  18. 18. Finkelshtein D, Werman A, Novick D, Barak S, Rubinstein M (2013) LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 110: 7306–7311. pmid:23589850
  19. 19. Saeed MF, Kolokoltsov AA, Albrecht T, Davey RA (2010) Cellular Entry of Ebola Virus Involves Uptake by a Macropinocytosis-Like Mechanism and Subsequent Trafficking through Early and Late Endosomes. PLoS Pathog 6: e1001110. pmid:20862315
  20. 20. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. (2006) Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol 80: 4174–4178. pmid:16571833
  21. 21. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM (2005) Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308: 1643–1645. pmid:15831716
  22. 22. Dube D, Brecher MB, Delos SE, Rose SC, Park EW, Schornberg KL, et al. (2009) The primed ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J Virol 83: 2883–2891. pmid:19144707
  23. 23. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, Nabel GJ. (2010) Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J Virol 84: 2972–2982. pmid:20053739
  24. 24. Marzi A, Reinheckel T, Feldmann H (2012) Cathepsin B & L are not required for ebola virus replication. PLoS Negl Trop Dis 6: e1923. pmid:23236527
  25. 25. Bale S, Liu T, Li S, Wang Y, Abelson D, Fusco M, et al. (2011) Ebola virus glycoprotein needs an additional trigger, beyond proteolytic priming for membrane fusion. PLoS Negl Trop Dis 5: e1395. pmid:22102923
  26. 26. Brecher M, Schornberg KL, Delos SE, Fusco ML, Saphire EO, White JM. (2012) Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change. Journal of virology 86: 364–372. pmid:22031933
  27. 27. Miller EH, Obernosterer G, Raaben M, Herbert AS, Deffieu MS, Krishnan A, et al. (2012) Ebola virus entry requires the host-programmed recognition of an intracellular receptor. The EMBO journal 31: 1947–1960. pmid:22395071
  28. 28. Cote M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, et al. (2011) Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477: 344–348. pmid:21866101
  29. 29. Wong AC, Sandesara RG, Mulherkar N, Whelan SP, Chandran K (2010) A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. Journal of virology 84: 163–175. pmid:19846533
  30. 30. White JM, Delos SE, Brecher M, Schornberg K (2008) Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit Rev Biochem Mol Biol 43: 189–219. pmid:18568847
  31. 31. Gregory SM, Harada E, Liang B, Delos SE, White JM, Tamm LK. (2011) Structure and function of the complete internal fusion loop from Ebolavirus glycoprotein 2. Proceedings of the National Academy of Sciences of the United States of America 108: 11211–11216. pmid:21690393
  32. 32. Gregory SM, Larsson P, Nelson EA, Kasson PM, White JM, Tamm LK. (2014) Ebolavirus entry requires a compact hydrophobic fist at the tip of the fusion loop. J Virol 88: 6636–6649. pmid:24696482
  33. 33. Weissenhorn W, Carfí A, Lee K- H, Skehel JJ, Wiley DC (1998) Crystal Structure of the Ebola Virus Membrane Fusion Subunit, GP2, from the Envelope Glycoprotein Ectodomain. Molecular Cell 2: 605–616. pmid:9844633
  34. 34. Jae LT, Raaben M, Herbert AS, Kuehne AI, Wirchnianski AS, Soh TK, et al. (2014) Virus entry. Lassa virus entry requires a trigger-induced receptor switch. Science 344: 1506–1510. pmid:24970085